This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Clovis Oncology And Array BioPharma Announce Agreement To Discover Novel Mutant KIT Inhibitor

Clovis Oncology, Inc. (Nasdaq: CLVS) and Array BioPharma (Nasdaq: ARRY) announced today an agreement for the discovery of a novel KIT inhibitor targeting resistance mutations for the treatment of GIST. GIST is a gastrointestinal cancer diagnosed each year in more than 12,000 patients in the US and EU and 2,500 in Japan. Currently approved therapies for GIST include the tyrosine kinase inhibitors (TKIs) Gleevec® (imatinib), and Sutent® (sunitinib), typically used first- and second-line respectively. Each inhibits some KIT mutations, but acquired resistance due to secondary KIT mutations occurs in the majority of GIST patients, resulting in disease progression. Patients who present with metastatic GIST have a five-year survival rate of approximately 50 percent.

Exon 17 resistance mutations are considered the most difficult to treat, and typically emerge after other TKI therapy in at least 50 percent of patients with progressive disease. None of the currently-approved therapies inhibit exon 17 mutations, nor do the current development-stage drugs targeting GIST. The goal of this collaboration is to discover a potent, oral inhibitor of KIT mutations, including all exon 17 resistance mutations.

“Virtually all GIST patients on first-line therapy progress due to the persistent and resistant nature of the disease,” said Dr. Jonathan Fletcher, Associate Professor, Harvard Medical School. “Therefore, there is significant unmet medical need for patients with advanced GIST. Specifically, we see a need for therapy active against the KIT exon 17 mutations.”

“Array has a proven track record of success in the discovery of novel drugs and we are very pleased to collaborate with them to identify our fourth product candidate,” said Patrick J. Mahaffy, president and CEO of Clovis Oncology. “This program is highly complementary to our current programs, takes advantage of our experience in developing targeted therapies with companion diagnostics and represents another cost effective approach to building our pipeline. If successful, we would hope to file an IND within three years, which is also well-timed as our existing pipeline matures.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.89 0.93%
FB $100.66 -3.30%
GOOG $688.45 0.71%
TSLA $154.27 -5.10%
YHOO $27.11 -3.10%


Chart of I:DJI
DOW 16,005.95 -21.10 -0.13%
S&P 500 1,837.86 -15.58 -0.84%
NASDAQ 4,225.5040 -58.2490 -1.36%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs